Key result
Dobutamine intravenous infusion in severe heart failure showed proportional steady-state plasma levels, an average total body clearance of 2.35 L/min/m2, and an elimination half-life of 2.37 min.
In patients with severe heart failure, dobutamine exhibits linear pharmacokinetics without saturation of disposition processes and has a short elimination half-life of approximately 2.4 minutes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dobutamine dosing in severe HF; larger studies needed to confirm PK parameters.
Dobutamine pharmacokinetics was investigated in 7 patients with severe cardiac failure. Dobutamine was administered by a constant intravenous infusion at rates of 2.5, 5.0, 7.5, and 10.0 microgram/kg/min. Steady-state plasma levels increased in proportion to the infusion rate, indicating that there was no saturation of the disposition processes. The average total body clearance was found to be 2.35 +/- 1.01 L/min/m2. After termination of the final infusion, plasma levels of dobutamine were monitored to determine the elimination half-life. The disappearance half-life of dobutamine was calculated to be 2.37 +/- 0.7 min and the distribution volume was 0.202 +/- 0.084 L/kg. The limited data suggest that the volume of distribution of dobutamine was related to the extent of edema.
No takes yet. Share an insight, caveat, or question.
Kates et al. (1978) studied severe cardiac failure (n=7). Dobutamine was evaluated on Pharmacokinetics (clearance, half-life, distribution volume). Dobutamine intravenous infusion in severe heart failure showed proportional steady-state plasma levels, an average total body clearance of 2.35 L/min/m2, and an elimination half-life of 2.37 min.
Synapse has enriched 10 related papers. Consider them for comparative context: